Extract
Mycobacterium abscessus complex (MABSC) is an emerging opportunistic pathogen complex responsible for lung infections after lung colonisation in people with pulmonary disorders, such as bronchiectasis or cystic fibrosis [1, 2]. It is becoming one of the most clinically relevant nontuberculous mycobacteria because of the severity of infection and poor response to antibiotic treatment. The MABSC includes three subspecies: M. abscessus abscessus, bolletii and massiliense [3–5]. MABSC pulmonary disease is characterised by the presence of specific microbiological, clinical and radiological features described in the ATS/ERS/ESCMID/ IDSA (American Thoracic Society/European Respiratory Society/European Society of Clinical Microbiology and Infectious Diseases/Infectious Diseases Society of America) consensus statement [1].
Abstract
This study identified innovative therapeutic targets to reinforce existing current antibiotic treatments against M. abscessus complex, exploiting a murine preclinical model of respiratory infection and 727 publicly available genomes from clinical isolates https://bit.ly/3eD4Pja
Footnotes
Animal studies were conducted according to protocols and adhering strictly to the Italian Ministry of Health guidelines for the use and care of experimental animals (IACUC No. 816) and approved by the San Raffaele Scientific Institute Institutional Animal Care and Use Committee (IACUC).
Conflict of interest: N.I. Lorè reports grants from US Cystic Fibrosis Foundation and Italian Cystic Fibrosis, outside the submitted work. P. Sander reports support from Swiss National Science Foundation, Cystic Fibrosis Switzerland and the Federal Office of Public Health for the present manuscript; and grants from InnoSuisse and Stiftung Wissenschaftliche Forschung, outside the submitted work. All other authors have nothing to disclose.
Support statement: P. Sander reports grants from the Swiss National Science Foundation, Cystic Fibrosis Switzerland and Federal Office of Public Health during the conduct of the study. N.I. Lorè reports grants from Italian Cystic Fibrosis Foundation (FFC 23#2020).
- Received August 5, 2022.
- Accepted October 12, 2022.
- Copyright ©The authors 2022. For reproduction rights and permissions contact permissions{at}ersnet.org
LIBRARY USERS
Log in through your institution
Purchase access
